Rchr
J-GLOBAL ID：200901037068719045   Update date: Mar. 13, 2024

Seimiya Hiroyuki

セイミヤ ヒロユキ | Seimiya Hiroyuki
Affiliation and department：
Japanese Foundation for Cancer Research Division of Molecular Biotherapy, Cancer Chemotherapy Center

About Japanese Foundation for Cancer Research Division of Molecular Biotherapy, Cancer Chemotherapy Center


Job title： Member and Chief
Homepage URL  (2)： https://www.jfcr.or.jp/chemotherapy/department/molecular_biotherapy/ ,  https://www.k.u-tokyo.ac.jp/en/gsfs/faculty/hiroyuki_seimiya/
Research field  (6)： Tumor biology ,  Tumor diagnostics and therapeutics ,  Pharmacology ,  Pharmaceuticals - health and biochemistry ,  Cell biology ,  Molecular biology
Research keywords  (36)： Chemical Biology ,  G4 ligand ,  Inhibitor ,  Biomarker ,  Pharmacodynamics ,  β-catenin ,  APC ,  Xenograft ,  Tumor suppressor gene ,  DNA repair ,  Genomic instability ,  Anticancer drug ,  Drug discovery ,  Tumor ,  Cancer ,  Drug screening ,  Cell division ,  Chromosome ,  Wnt signal ,  Cell immortalization ,  Cell growth ,  Drug resistance ,  Synthetic lethality ,  DNA damage ,  Chemotherapy ,  Predictive biomarker ,  Cellular senescence ,  Molecular profiling ,  Poly(ADP-ribosyl)ation ,  G-quadruplex ,  Molecular targeted therapy ,  Cancer stem cells ,  PARP ,  Tankyrase ,  Telomerase ,  Telomere
Research theme for competitive and other funds  (49)：
  • 2022 - 2028 生命科学連携推進協議会
  • 2022 - 2028 先端モデル動物支援プラットフォーム
  • 2022 - 2025 ポリADPリボシル化酵素タンキラーゼを標的としたがん精密医療の分子基盤
  • 2021 - 2025 Investigation of novel molecular targets for oral cancer stem cells and establishment of novel oral cancer treatment strategy
  • 2023 - 2025 Development of cancer medicine targeting G-quadruplex-mediated regulation of translation
Show all
Papers (124)：
  • Shiho Hirose, Tetsuo Mashima, Xunmei Yuan, Makiko Yamashita, Shigehisa Kitano, Shinichi Torii, Toshiro Migita, Hiroyuki Seimiya. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma. Cancer Science. 2024
  • Shun Morino, Tetsuo Mashima, Fumiyuki Shirai, Satoshi Nagayama, Ryohei Katayama, Hiroyuki Seimiya. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer Letters. 2024. 584. 216632-216632
  • Masatomo Chiba, Kenichi Miyata, Hikaru Okawa, Yoko Tanaka, Koji Ueda, Hiroyuki Seimiya, Akiko Takahashi. YBX1 Regulates Satellite II RNA Loading into Small Extracellular Vesicles and Promotes the Senescent Phenotype. International Journal of Molecular Sciences. 2023. 24. 22. 16399-16399
  • Mingjue Chen, Tetsuo Mashima, Taichi Oishi, Yukiko Muramatsu, Yosuke Seto, Manabu Takamatsu, Naomi Kawata, Shun Morino, Ayane Nakamura, Saori Inaba, et al. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British Journal of Cancer. 2023. 130. 1. 151-162
  • Yoshihiro Mezawa, Tingwei Wang, Yataro Daigo, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Liying Yang, Reo Maruyama, Hiroyuki Seimiya, et al. Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts. Cancer science. 2023
ｍore...
MISC (170)：
ｍore...
Patents (17)：
ｍore...
Books (1)：
  • Drug discovery for cancer
    Kagakudojin 2019 ISBN:9784759817331
Lectures and oral presentations  (127)：
  • Telomere as the starting point of anticancer drug discovery
    (LyonSE&N - ELyT Workshop 2020 2020)
  • テロメアから始まるがん創薬
    (JSPS「日本におけるケミカルバイオロジーの新展開」 に関する産学協力研究委員会 2019)
  • ケミカルツールを利用した四重鎖核酸の統合機能解析とその応用
    (化学コミュニケーションのフロンティア 第6回公開シンポジウム 2019)
  • Revisiting the paradoxical telomere shortening in cancer
    (MBSJ2019 Workshop 2019)
  • Telomere as the starting point of anticancer drug discovery
    (The 7th Symposium, RIKEN-Max Planck Joint Research Center 2019)
ｍore...
Education (2)：
  • 1990 - 1995 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
  • 1986 - 1990 The University of Tokyo Faculty of Pharmaceutical Sciences Department of Pharmacy
Professional career (1)：
  • Ph.D. (The University of Tokyo)
Work history (11)：
  • 2020/04 - 現在 The University of Tokyo Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences Visiting Professor (concurrent)
  • 2018/05 - 現在 RIKEN Program for Drug Discovery and Medical Technology Platforms Project Leader (concurrent)
  • 2009/08 - 現在 The University of Tokushima Institute of Health Biosciences The University of Tokushima Graduate School Visiting Professor (concurrent)
  • 2008/04 - 現在 Meiji Pharmaceutical University Graduate School of Pharmaceutical Sciences Visiting Professor (concurrent)
  • 2005/01 - 現在 Japanese Foundation for Cancer Research Division of Molecular Biotherapy, Cancer Chemotherapy Center Member and Chief
Show all
Committee career (16)：
  • 2017 - 現在 Journal of Biological Chemistry Editorial Board Member
  • 2016/04 - 現在 Platform of Advanced Animal Model Support (AdAMS), Grant-in-Aid for Scientific Research on Innovative Areas, Ministry of Education, Culture, Sports, Science and Technology, Japan Member, General Management Group (2022-); Group Leader, Molecular Profiling Committee (2016-2022); Member of Executive Committee of the Technical Training Course for Young Scientists
  • 2014 - 現在 Japanese Society of Medical Oncology Member of Education Planning Subcommittee (2014-2019); Member of Terminology Subcommittee (2015-2018); Member of Program Committee of the 14th Annual Meeting (2016)
  • 2013 - 現在 Pharmaceuticals and Medical Devices Agency (PMDA) External Expert (2013-); Member of Working Group for Non-clinical Pharmacology Studies on Anticancer Drugs (2013, 2015-2016)
  • 2009 - 現在 Japanese Association for RNA Interference Councilor (2009-); Chairman of Program Committee of the 4th Annual Meeting
Show all
Awards (5)：
  • 2019 - JFCR Academic Award
  • 2017 - The Japanese Association for Molecular Target Therapy of Cancer Takashi Tsuruo Award
  • 2016 - JCA-Mauvernay Award Telomere maintenance system as an anticancer therapeutic target
  • 2004 - Japanese Cancer Association Incitement Award
  • 2000 - NCI-JFCR Scientist Exchange Program Fellow Regulation of telomere dynamics by tankyrase
Association Membership(s) (10)：
Japanese Association for RNA Interference ,  Anti-Tumor Drug Development Forum ,  関東ホルモンと癌研究会 ,  The Japanese Association for Molecular Target Therapy of Cancer ,  American Association for Cancer Research ,  Japanese Cancer Association ,  The JFCR International Symposium on Cancer Chemotherapy ,  Japanese Society of Medical Oncology ,  The Pharmaceutical Society of Japan ,  Molecular Biology Society of Japan
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM